Loading…

MS-23 IMPROVING FORWARD INFUSION PRESSURE IN VASCULAR BRAIN TUMORS USING A DOUBLE CATHETER AND COIL TECHNIQUE

BACKGROUND: Intra-arterial infusion into vascular brain tumors can be difficult due to high intraluminal back pressures. We developed a double catheter and coil technique to improve forward penetration while minimizing backflow. METHODS: Patients undergoing preoperative embolization underwent angiog...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2014-11, Vol.16 (suppl 5), p.v131-v131
Main Authors: Singel, S., Hicks, S., Dawson, A., Fonkem, E., Noonan, P.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Intra-arterial infusion into vascular brain tumors can be difficult due to high intraluminal back pressures. We developed a double catheter and coil technique to improve forward penetration while minimizing backflow. METHODS: Patients undergoing preoperative embolization underwent angiographic evaluation of the tumor vascularity. The embolic agent N-Butyl-Cyanoacrylate (NBCA) was chosen to achieve obliteration of the vascular bed. An occlusive micro-catheter was placed at the orifice of the principal feeding artery. A second, coaxial, microcatheter was advanced into the tumor supply vessel. A coil was then deployed proximally through the first catheter to create a buttress for the NBCA and to effectively prevent any backflow of embolization agent. RESULTS: Backflow into the access vessel was prevented in all cases. Sufficient anterograde pressure gradients were maintained to achieve penetration of NBCA into the entire tumor. Post-procedural angiogram did not reveal any vessel truncations, distal embolization or residual tumor staining. CONCLUSIONS: Sufficient anterograde tumor penetration with NBCA can be achieved using a double catheter and proximal coil strategy. This technique may prove useful to infuse tumors with high viscosity therapeutics.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/nou260.22